IDegLira DUAL IX

DUAL IX was published in

• NEJM 2018

• Diabetes Care 2019

• Lancet 2019

• Diabetes Obesity Metabolism 2019

The primary authors include all except

• Athena Philis-Tsimikas

• Liana K. Billings

• Robert Busch

• Martin Haluzík

DUAL IX was [A] ____, [B] ____ conducted at 74 sites in [C] ___

• [A] 26 weeks

  [B] phase 3b

  [C] 11 countries

• [A] 52 weeks

  [B] phase 3a

  [C] 10 countries

• [A] 104 weeks

  [B] phase 3b

  [C] 12 countries

• [A] 26 weeks

  [B] phase 3a

  [C] 11 countries

Inclusion criteria included all except

• BMI ≥20 and <40 kg/m²

• Age > 18 years

• using Basal insulin 20-50U

• SGLT2i +/- OADs

The HbA1c reduction over time

• IDegLira -1.94%

• IGlar -1.68%

• ETD -0.36%

• All of above

Superiority of IDegLira over IGlar U100 was confirmed for

• Body weight

• severe or blood-glucose-confirmed symptomatic

  hypoglycaemia

• total daily insulin dose

• SMPG

• All of above

IDegLira was initiated at a dose step of

• 10 U

• 16 dose steps

• 10 dose steps

• 16 U

The trials are done in accordance with

• International Conference on Harmonisation

  Good Clinical Practice

• Declaration of Helsinki

• Both

Which SGLT2i was used most at the baseline distribution

• empagliflozin

• dapagliflozin

• canagliflozin

• ertugliflozin

DUAL IX Body weight change ETD was

• -1.92kg

• -3.0kg

• -1.5kg

• -2.5kg